BridgeMD
New treatment option for Metastatic Triple Negative Breast Cancer
Official title The TASTY-steering Study
ClinicalTrials.gov ID: NCT07258563
What this study is testing
- What it's testing
- This is a multicentre non-blinded randomised intervention trial with a parallel cluster design. The multicentre study will be performed at 12 hospitals in the Netherlands.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Age ≥18 and ≤70 years
- Indication to start chemotherapy for:
- Metastatic triple negative breast cancer
- Metastatic testicular cancer
- Stage II-IV diffuse large B cell lymphoma
You likely can't join if
- Pregnancy
- Currently experiencing taste or smell problems
- Previous or current radiotherapy of head and neck region
- Enteral feeding through tube or parenteral feeding
- Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
- Chronic (\>1 month) high dose corticosteroids (\>10 mg prednisone/day or equivalent).
See the full eligibility criteria
- Age ≥18 and ≤70 years
- Indication to start chemotherapy for:
- Metastatic triple negative breast cancer
- Metastatic testicular cancer
- Stage II-IV diffuse large B cell lymphoma
- Chemotherapy scheduled to start in the next 6 weeks
- Consuming solid foods and drinks is possible
- ≤50% of recommended daily intake in kcal consists of oral nutritional supplements
- Oral mucositis grade ≤2 (Common Terminology Criteria for Adverse Events, version 5.0)
- Ability to comply with all protocol-required actions
- Written informed consent
- For the intervention phase only: subjective change in taste since start of chemotherapy
- Pregnancy
- Currently experiencing taste or smell problems
- Previous or current radiotherapy of head and neck region
- Enteral feeding through tube or parenteral feeding
- Participation in another clinical trial aimed at preventing or treating taste and/or smell alterations
- Chronic (\>1 month) high dose corticosteroids (\>10 mg prednisone/day or equivalent).
The study team makes the final eligibility decision.
Where it's taking place
- Amsterdam, Netherlands
- Arnhem, Netherlands
- Dirksland, Netherlands
- Ede, Netherlands
- Groningen, Netherlands
- Nijmegen, Netherlands
- Rotterdam, Netherlands
- Scheemda, Netherlands
- Veldhoven, Netherlands
- Zwolle, Netherlands
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Amsterdam, Netherlands; Arnhem, Netherlands; Dirksland, Netherlands; Ede, Netherlands; Groningen, Netherlands; Nijmegen, Netherlands and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.